720 related articles for article (PubMed ID: 17352646)
1. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
[TBL] [Abstract][Full Text] [Related]
3. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
Serra AL; Wuhrmann C; Wüthrich RP
Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
[TBL] [Abstract][Full Text] [Related]
4. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
5. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
6. Renal Phosphate Wasting Due to Tumor-Induced (Oncogenic) Osteomalacia.
Amaratunga EA; Ernst EB; Kamau J; Kotala R; Snyder R
Cureus; 2021 Jun; 13(6):e15507. PubMed ID: 34268038
[TBL] [Abstract][Full Text] [Related]
7. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
[TBL] [Abstract][Full Text] [Related]
9. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
11. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
13. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
Boland JM; Tebben PJ; Folpe AL
J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced osteomalacia: lessons learned.
Lewiecki EM; Urig EJ; Williams RC
Arthritis Rheum; 2008 Mar; 58(3):773-7. PubMed ID: 18311810
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
[TBL] [Abstract][Full Text] [Related]
16. Effects of cinacalcet in renal transplant patients with hyperparathyroidism.
Courbebaisse M; Diet C; Timsit MO; Mamzer MF; Thervet E; Noel LH; Legendre C; Friedlander G; Martinez F; Prié D
Am J Nephrol; 2012; 35(4):341-8. PubMed ID: 22473131
[TBL] [Abstract][Full Text] [Related]
17. FGF-23 is elevated by chronic hyperphosphatemia.
Gupta A; Winer K; Econs MJ; Marx SJ; Collins MT
J Clin Endocrinol Metab; 2004 Sep; 89(9):4489-92. PubMed ID: 15356053
[TBL] [Abstract][Full Text] [Related]
18. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
20. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]